A study for prevention and treatment of complications associated with fluid extravasation during shoulder arthroscopy by perioperative intervention

A study for prevention and treatment of complications associated with fluid extravasation during shoulder arthroscopy by perioperative intervention?

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900023793

Enrollment

Unknown

Registered

2019-06-12

Start date

2019-07-01

Completion date

Unknown

Last updated

2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications associated with fluid extravasation during shoulder arthroscopy

Interventions

Group 1:furosemide

Group 2:methylprednisolone

Group 3:ulinastatin

Group 4:saline

Group 5 :furosemide+ methylprednisolone

Group 6:furosemide+ulinastatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are to receive shoulder arthroscopy; 2. Aged 18 to 60 years, ASA I to II; 3. BMI 18kg/m2 to 30kg/m2; 4. Normal cognitive function; 5. Fully understand the test, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Variation or alteration of the neck and chest; 2. Allergy to thiazide diuretics, methylprednisolone, ulinastatin, ropivacaine and other drug ingredients or components; 3. Uncontrolled hypertension and diabetes (systolic blood pressure =160mmHg, or diastolic blood pressure =100mmHg, blood glucose =15mmol/L); 4. OSAHS or epilepsy; 5. Psychotropic or narcotic drug abuse, pregnancy or breastfeeding; 6. Unable to perform brachial plexus nerve block (skin infection, brachial plexus nerve injury); 7. Severe liver or kidney disease, confirmed pulmonary hypertension, heart failure (NYHA>II), coronary heart disease; 8. Abnormal coagulation function; 9. Other conditions in which the patients are not suitable for the clinical trial; 10. Abnormal coagulation function; 11. Other conditions in which the patients were not suitable for the clinical trial.

Design outcomes

Primary

Measure	Time frame
1.Edema in adjacent soft tissue;2.Evaluation of the lung edema;	—

Countries

China

Contacts

Public ContactLan Zhang

63637936@qq.com+86 13438316506

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026